Featured Research

from universities, journals, and other organizations

Genetic predisposition to liking amphetamine reduces risk of schizophrenia, ADHD

Date:
April 7, 2014
Source:
University of Chicago Medical Center
Summary:
Genetic variants associated with enjoying the effects of d-amphetamine -— the active ingredient in Adderall -— are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists. "Some of the variants that make you like amphetamine also appear to make you less likely to develop schizophrenia and ADHD," said study leader. "Our study provides new insights into the biology of amphetamine and how it relates to the biology of risk for these psychiatric diseases."

Genetic variants associated with enjoying the effects of d-amphetamine -- the active ingredient in Adderall -- are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of amphetamine, is related to schizophrenia and ADHD.

Related Articles


"Some of the variants that make you like amphetamine also appear to make you less likely to develop schizophrenia and ADHD," said study leader Abraham Palmer, PhD, associate professor of human genetics at the University of Chicago. "Our study provides new insights into the biology of amphetamine and how it relates to the biology of risk for these psychiatric diseases."

Palmer and his team previously conducted a genome-wide association study (GWAS) to identify genetic variants associated with experiencing the euphoric effects of amphetamine, which is thought to affect risk for drug abuse. Almost 400 volunteers were given d-amphetamine in a double-blind, placebo-controlled experiment. They were then asked to report how the drug made them feel using carefully designed questionnaires. The researchers measured genetic differences between these subjects at approximately a million sites throughout the genome to identify variations in the DNA code known as single nucleotide polymorphisms, or SNPs. They assessed the relationships between each of these SNPs and sensitivity to amphetamine.

Using data from other large-scale GWAS studies, the team examined these same SNPs for possible overlapping associations with psychiatric disorders. Through rigorous statistical testing they found that an unexpectedly large number of SNPs were associated with both sensitivity to amphetamine and risk of developing schizophrenia or ADHD. This suggested that these traits are influenced by a common set of genetic variants. Moreover, a significant proportion of this observed overlap appeared to be caused by variants that increased enjoyment of the effects of amphetamine but decreased the risk for both psychiatric diseases.

The researchers performed similar analyses for traits that were not expected to be related to amphetamine sensitivity, such as height, irritable bowel disease and Parkinson's disease. In all of these cases they observed no more overlapping SNPs than would have been expected by chance alone.

"While this approach would not be a useful diagnostic test, we expect that people who like the effects of amphetamine would be slightly less likely to develop schizophrenia and ADHD," Palmer said. "And people who did not like amphetamine, we would predict, are slightly more likely to develop these diseases."

"What is particularly striking is that by examining people's responses for just a few hours after taking a drug, we can identify an underlying genetic propensity that can manifest as a psychiatric disease over the course of a lifetime," he adds.

These results provide unique genetic evidence for the role of dopamine in schizophrenia and ADHD. Schizophrenia is commonly treated using drugs that block dopamine signaling, while ADHD is treated using drugs, including d-amphetamine itself, that enhance dopamine signaling. Despite opposite treatments, amphetamine-liking SNPs reduced the risk for developing both diseases, suggesting that dopamine's role is more complex than hypothesized.

The study also offers a new direction for the analysis of a wide range of similar genetic studies, particularly ones with smaller sample sizes. By analyzing the results of those studies for overlap with data from much larger genetic studies, promising genetic variants that would otherwise never stand out among the noise of hundreds of thousands of other random variants can be identified.

"Our approach offers a promising new direction for studying complex psychiatric behaviors using the whole-genome approach," said co-author Harriet de Wit, PhD, professor of psychiatry and behavioral neuroscience at the University of Chicago. The team plans to further study the SNPs identified in this study for their functional roles in amphetamine liking, schizophrenia and ADHD. In addition, Palmer hopes to explore genetic predispositions toward liking or disliking other therapeutic drugs and whether sensitivity to those drugs might also overlap with the diseases for which these drugs are used.

"When we use a drug treatment, we know exactly what systems have been perturbed," Palmer said. "So when we see overlap for alleles that affect how you respond to drugs and a disease, we can hone in on what those alleles are doing biologically. This is instrumental for translating those results into new treatments and cures, which is the ultimate reason for performing genetic studies of disease."


Story Source:

The above story is based on materials provided by University of Chicago Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. B. Hart, E. R. Gamazon, B. E. Engelhardt, P. Sklar, A. K. Kahler, C. M. Hultman, P. F. Sullivan, B. M. Neale, S. V. Faraone, H. de Wit, N. J. Cox, A. A. Palmer, R. Anney, P. Asherson, T. Banaschewski, M. Bayes, J. Biederman, J. K. Buitelaar, M. Casas, B. Cormand, J. Crosbie, A. E. Doyle, J. Elia, S. V. Faraone, B. Franke, L. Kent, J. Kuntsi, K.-P. Lesch, S. K. Loo, J. J. McGough, S. E. Medland, B. Neale, S. F. Nelson, R. D. Oades, J. A. Ramos-Quiroga, A. Reif, M. Ribases, A. Rothenberger, R. Schachar, S. L. Smalley, E. Sonuga-Barke, H.-C. Steinhausen, A. Thapar, N. Williams. Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder. Proceedings of the National Academy of Sciences, 2014; DOI: 10.1073/pnas.1318810111

Cite This Page:

University of Chicago Medical Center. "Genetic predisposition to liking amphetamine reduces risk of schizophrenia, ADHD." ScienceDaily. ScienceDaily, 7 April 2014. <www.sciencedaily.com/releases/2014/04/140407153804.htm>.
University of Chicago Medical Center. (2014, April 7). Genetic predisposition to liking amphetamine reduces risk of schizophrenia, ADHD. ScienceDaily. Retrieved November 1, 2014 from www.sciencedaily.com/releases/2014/04/140407153804.htm
University of Chicago Medical Center. "Genetic predisposition to liking amphetamine reduces risk of schizophrenia, ADHD." ScienceDaily. www.sciencedaily.com/releases/2014/04/140407153804.htm (accessed November 1, 2014).

Share This



More Health & Medicine News

Saturday, November 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins